FDMT

4D Molecular Therapeutics, Inc. (FDMT) | Rumor.io

4D Molecular Therapeutics

FDMT

Attention (50-day avg)0%

Attention rank (50-day avg)#2,070

Bullish sentiment (50-day avg)85%

Price to earnings ratio-6.02

Market capitalization804.4M

Earnings per share-2.63

Dividend yield (TTM)—

Revenue (annual)85.2M

Net income (annual)-140.1M

Social

What share of all stock conversation is about FDMT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 17

4D Molecular Therapeutics, Inc. (FDMT) stock rose ~12.0% due to clinical gene therapy progress.
The company's lead gene therapy candidate, 4D-150, is a key factor in FDMT's market momentum.
FDMT has hit a new 52-week high, with the next target at $17.20, driven by decent trading volumes.

Generated by AI

Sentiment

Of the messages about FDMT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +14.58	79.59% +0
Bearish	—	0%	0% -14.58	20.41% 0

Bullish· Aug 5

$FDMT has significant upside potential, with some analysts predicting a 5x increase in value.
The company's recent clinical trial results for its 4D-150 treatment are positive, with analysts' 12-month price targets ranging from $25 to $44.
The stock is experiencing a short squeeze, with a high borrow rate of 43% and some analysts predicting a price increase to $15 or higher.

Bearish· Aug 1

The market is rigged and the asset is being manipulated by a group that wants to hold it for themselves.
The asset's price is expected to drop below $6, with some predicting a retrace back to the mid $6's.
The asset's price is being dumped, with a large volume of shares being sold, and some investors are warning that it's going to break below $6.

Generated by AI

Topics

Of the messages about FDMT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	80%	65.94%
Analysts	0%	0%	0%	20.78%
Technical Analysis	0%	0%	0%	7.03%
Controversies	0%	0%	20%	0.31%
Earnings	0%	0%	0%	1.09%
Macro	0%	0%	0%	4.84%

Oct 31

4D Molecular Therapeutics, Inc. (FDMT) has announced an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific region.
The deal includes an $85 million upfront payment to FDMT, as well as at least $50 million in cost sharing over three years, with potential milestones of up to $336 million.
FDMT retains global rights to 4D-150 outside of the Asia-Pacific region and will lead the Phase 3 clinical trial, with APAC sites expected to open by the end of 2025.

Generated by AI

Community

Of the messages about FDMT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.33%	75%	40.3%	62.07%
Newcomers	16.67%	25%	59.7%	37.93%

Regulars· Feb 5

The stock price of 4D Molecular Therapeutics ($FDMT) has seen significant gains, with shares up 27% in a single day and a 70% increase in premarket trading.
The company's recent positive trial data has contributed to the stock's surge, with shares rising 33% following the announcement.
$FDMT has also seen a significant increase in market capitalization, reaching $750M, which some participants believe could lead to further price growth.

Newcomers· Feb 6

Newcomers to the stock are excited about its 84.62% increase, with some mentioning the stock's strong offering and others enjoying trading it on the day.
The company's recent positive Phase 2 results are being cited as a key factor in the stock's performance, with some users noting the potential implications for the company's future.
The stock's float and volume are being discussed, with some users noting the significant increase in float rotation and the stock's strong gains, including an 83% increase.

Generated by AI

News

4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway

14h agoSeeking Alpha

4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema

4D Molecular Therapeutics (FDMT) has enrolled the first patients in a phase 3 trial of 4D-150 in dia

1d agoYahoo Finance

4D Molecular starts Phase 3 trial for diabetic eye disease drug

1d agoInvesting.com

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial (N=514) evaluating 4D-150 in a treatment-naïve DME populationUpdated 2-year data from SPECTRA Part 1 clinical trial in DME continue to demonstrate a favorable safety profile, durable vision and anatomic improvements and clinically meaningful treatment burden reduction EMERYVILLE, Calif., Sept. 28, 2

1d agoYahoo Finance UK

4D molecular therapeutics CEO Kirn sells $811,003 in stock

13d agoInvesting.com

4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing

David Kirn, Director, President and Chief Executive Officer, on September 14, 2026, sold 58,333 shar

14d agoYahoo Finance

Also Discussed

Investors talking about FDMT also mention

#	Name	Attention
1	Regenxbio Inc.RGNX	0%+0
2	Arvinas, Inc.ARVN	0%+0
3	ADVM - Adverum Biotechnologies, Inc.	——
4	MeiraGTx Holdings plcMGTX	0%new
5	APLS - Apellis Pharmaceuticals, Inc.	——
6	Caribou Biosciences, Inc.CRBU	0%0
7	Denali Therapeutics Inc.DNLI	0%new
8	Monte Rosa Therapeutics, Inc.GLUE	0%0
9	Century Therapeutics IncIPSC	0%0
10	Cabaletta Bio Inc.CABA	0%0

4D Molecular Therapeutics, Inc.

Healthcare
Biotechnology

4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform. The company designs customized adeno-associated virus, or AAV, vectors intended to deliver therapeutic payloads to specific tissues and disease areas with precision. Its current clinical development programs are concentrated in retina and pulmonology, reflecting a portfolio aimed at treating serious conditions through targeted gene delivery. In ophthalmology, the company is advancing therapies for retinal vascular diseases and other eye disorders, while its respiratory work includes programs for lung-directed treatment of genetic disease. 4D Molecular Therapeutics, Inc. plays a specialized role in the gene therapy market by combining vector engineering, tissue targeting, and disease-focused development to support next-generation genetic medicine candidates.

Website

Location

5858 Horton Street

EmeryVille, CA, 94608

United States

Social

What share of all stock conversation is about FDMT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Aug 17

4D Molecular Therapeutics, Inc. (FDMT) stock rose ~12.0% due to clinical gene therapy progress.
The company's lead gene therapy candidate, 4D-150, is a key factor in FDMT's market momentum.
FDMT has hit a new 52-week high, with the next target at $17.20, driven by decent trading volumes.

Generated by AI

Sentiment

Of the messages about FDMT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +14.58	79.59% +0
Bearish	—	0%	0% -14.58	20.41% 0

Bullish· Aug 5

$FDMT has significant upside potential, with some analysts predicting a 5x increase in value.
The company's recent clinical trial results for its 4D-150 treatment are positive, with analysts' 12-month price targets ranging from $25 to $44.
The stock is experiencing a short squeeze, with a high borrow rate of 43% and some analysts predicting a price increase to $15 or higher.

Bearish· Aug 1

The market is rigged and the asset is being manipulated by a group that wants to hold it for themselves.
The asset's price is expected to drop below $6, with some predicting a retrace back to the mid $6's.
The asset's price is being dumped, with a large volume of shares being sold, and some investors are warning that it's going to break below $6.

Generated by AI

Topics

Of the messages about FDMT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	80%	65.94%
Analysts	0%	0%	0%	20.78%
Technical Analysis	0%	0%	0%	7.03%
Controversies	0%	0%	20%	0.31%
Earnings	0%	0%	0%	1.09%
Macro	0%	0%	0%	4.84%

Oct 31

4D Molecular Therapeutics, Inc. (FDMT) has announced an exclusive license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific region.
The deal includes an $85 million upfront payment to FDMT, as well as at least $50 million in cost sharing over three years, with potential milestones of up to $336 million.
FDMT retains global rights to 4D-150 outside of the Asia-Pacific region and will lead the Phase 3 clinical trial, with APAC sites expected to open by the end of 2025.

Generated by AI

Community

Of the messages about FDMT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.33%	75%	40.3%	62.07%
Newcomers	16.67%	25%	59.7%	37.93%

Regulars· Feb 5

The stock price of 4D Molecular Therapeutics ($FDMT) has seen significant gains, with shares up 27% in a single day and a 70% increase in premarket trading.
The company's recent positive trial data has contributed to the stock's surge, with shares rising 33% following the announcement.
$FDMT has also seen a significant increase in market capitalization, reaching $750M, which some participants believe could lead to further price growth.

Newcomers· Feb 6

Newcomers to the stock are excited about its 84.62% increase, with some mentioning the stock's strong offering and others enjoying trading it on the day.
The company's recent positive Phase 2 results are being cited as a key factor in the stock's performance, with some users noting the potential implications for the company's future.
The stock's float and volume are being discussed, with some users noting the significant increase in float rotation and the stock's strong gains, including an 83% increase.

Generated by AI

4D Molecular Therapeutics

Social

Aug 17

Bullish· Aug 5

Bearish· Aug 1

Oct 31

Regulars· Feb 5

Newcomers· Feb 6

4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway

4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema

4D Molecular starts Phase 3 trial for diabetic eye disease drug

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

4D molecular therapeutics CEO Kirn sells $811,003 in stock

4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing

Also Discussed

4D Molecular Therapeutics, Inc.

Company Information

Location

4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway

4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema

4D Molecular starts Phase 3 trial for diabetic eye disease drug

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

4D molecular therapeutics CEO Kirn sells $811,003 in stock

4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing

Also Discussed

Social

Aug 17

Bullish· Aug 5

Bearish· Aug 1

Oct 31

Regulars· Feb 5

Newcomers· Feb 6